Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling-Guided Therapy for Carcinoma of Unknown Primary
NCT00737243Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2008
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and erlotinib in carcinoma of unknown primary (CUP) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Survival at 18 months. Started Aug 2008; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00737243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00737243.